Skip to main content
. 2015 May 29;5(5):e316. doi: 10.1038/bcj.2015.39

Figure 6.

Figure 6

In vivo efficacy of 7-1C-mcMMAF and 67-7A-mcMMAF in AML xenograft models. Six- to 8-week-old CB17 mice were subcutaneously injected with OCI-AML3 (a and c) or THP1 (b) cells. (a and b) Four groups of six to nine mice were treated with 3 mg/kg of control-mcMMAF (empty circle), 67-7A-mcMMAF (black circle) and 7-1C-mcMMAF (gray square) or 150- mg/kg cyclophosphamide (empty triangle) according to the schedule indicated by the arrowheads. Data shown in a and b are from one representative of two independent experiments. (c) CB17 mice injected with OCI-AML3 were treated with 3 mg/kg of unconjugated control antibody (empty circle), 67-7A (black circle) and 7-1C (gray square) or 150 mg/kg cyclophosphamide (empty triangle) according to the schedule indicated by the arrowheads. No activity was detected with unconjugated antibodies compared with isotype control antibody. The tumor values at the end of study (mean and standard deviation (STDEV)) are used to calculate significance. NS, not significant.